Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
ConditionThyroid Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T
Eligibility criteria
Qualifiers
Participant must provide voluntary, written informed consent to participate in this clinical investigation.
Participant agrees to comply with all study procedures, including all follow-up visits.
Participant with a Bethesda VI cytology (tumor size <= 1.5 cm, no known regional/distant metastases)
Participant with a Bethesda V cytology and normal calcitonin levels.
Disqualifiers
FNA findings suggestive of high-grade malignancy
Presence of regional or distant lymph node metastases.
Participant had a history of previous neck irradiation.
Females who are pregnant at time of enrollment.
Trial design
Treatments tested in this trial
- CellFX nsPFA Percutaneous Electrode System
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov